Pharmaceutical Biotechnology

Molecular Biotechnology.- Biophysical and biochemical analysis of recombinant proteins.- Production and downstream processing of biotech products.- Formulation of biotech products, including biopharmaceutical considerations.- Pharmacokinetics and pharmacodynamics of peptide and protein drugs.- Immunogenicity of pharmaceutical proteins.- General considerations of monoclonal antibodies from structure to therapeutic application.- Genomics, Other "Omics" Technologies, Personalized Medicine and Additional Biotechnology-Related Techniques.- Dispensing biotechnology products: handling, professional education and product information.- Economic considerations in medical biotechnology.- Regulatory framework for biosimilars.- Vaccines.- Oligonucleotides and siRNA.- Gene therapy.- Stem cell technology.- Therapeutic Applications.-Endocrinology.- Insulin.- Follicle-stimulating hormone.-  Growth hormone.- Cardiovascular and Respiratory Applications.- Recombinant coagulation factors and thrombolytics.- Recombinant human deoxyribonuclease.- Oncology.- Monoclonal antibodies in oncology .- Hematopoetic growth factors.- Inflammation and Immunemodulation.- Monoclonal antibodies in transplantation.- Monoclonal antibodies and antibody-based therapeutics in anti-inflammatory therapy.-  Interferons and interleukins.- Anti-infectious diseases.- Monoclonal antibodies.- Enzyme replacement therapy.

Daan J.A. Crommelin is Professor Emeritus, Department of Pharmaceutical Sciences, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherland. He is an elected fellow of the International Pharmaceutical Federation (FIP) and the American Association of Pharmaceutical Scientists (AAPS).




Robert D. Sindelar is a Professor and Dean Emeritus, Faculty of Pharmaceutical Sciences, The University of British Columbia (UBC). He is an elected fellow of the Canadian Academy of Health Sciences, and an elected fellow of the International Pharmaceutical Federation (FIP). He previously served as Vice President of Innovation, Research & Academic Affairs at Providence Health Care (PHC), President of the PHC Research Institute and Associate Dean Research in the UBC Faculty of Medicine





Bernd Meibohm is Distinguished Professor, Associate Dean for Research and Graduate Programs, and Chair of the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center College of Pharmacy, Memphis, Tennessee, USA. He is an elected fellow of the American College of Clinical Pharmacology (ACCP) and the American Association of Pharmaceutical Scientists (AAPS).